乳腺癌耐药蛋白表达与晚期非小细胞肺癌铂类为主的化疗疗效及预后的关系

Relationship between breast cancer resistance protein and response to platinum-based chemotherapy as well as prognosis in advanced non-small cell lung cancer

目的探讨乳腺癌耐药蛋白(BCRP)表达与晚期非小细胞肺癌(NSCLC)以铂类为主的化疗疗效及预后的关系。方法回顾性分析本院初治的B或期NSCLC患者86例,应用免疫组化方法检测每位患者肿瘤标本中的BCRP表达水平,应用SPSS 16.0进行统计分析,探讨BCRP表达水平与化疗疗效、无进展生存期(PFS)以及总生存期(OS)的关系。结果BCRP表达阴性患者的化疗有效率为44.0%,而表达阳性的患者为19.4%,两者之间差异有统计学意义(P=0.017)。BCRP表达阴性患者的PFS及OS较表达阳性的患者长,并且差异有统计学意义(P值分别为0.000和0.000)。多因素分析表明BCRP是独立影响PFS及OS的指标。结论BCRP表达水平与晚期NSCLC以铂类为主的化疗疗效及预后密切相关,对于进一步研究晚期NSCLC耐药机制,制定个体化治疗方案,延长患者生存期具有重要意义。

Objective To investigate the relationship between the expression level of breast cancer resistance protein（BCRP） and response to platinum-based chemotherapy as well as prognosis in advanced non-small cell lung cancer（NSCLC）.Methods Eighty-six cases with untreated stage ⅢB or Ⅳ NSCLC were reviewed.The expression level of BCRP was examined immunohistochemically in all patients＇ tumor samples.The relationship between the expression level of BCRP and response to chemotherapy,progression-free survival（PFS） as well as overall survival（OS） were analyzed by SPSS 16.0.Results The response rate to chemotherapy of BCRP-negative patients was 44.0%,as opposed to 19.4% in BCRP-positive patients.This difference was statistically significant（P=0.017）.BCRP-negative patients had longer PFS（P=0.000） and OS（P=0.000） than BCRP-positive patients.Multivariate analysis confirmed BCRP was an independent variable related to PFS and OS.Conclusions The relationship between the expression level of BCRP and respons...更多e to platinum-based chemotherapy as well as prognosis in advanced NSCLC is very close.It can help to further study on the mechanism of drug resistance to chemotherapy in advanced NSCLC patients so as to establish the individual therapeutic regimens and prolong the survival time of patients.